Healthcare Industry News: RaySearch
News Release - January 27, 2009
First product from collaboration between RaySearch and TomoTherapy receives FDA clearanceSTOCKHOLM, Sweden--(HSMN NewsFeed)--RaySearch Laboratories AB (STO:RAYB) and TomoTherapy Inc. announced today that the new software solution SharePlan(TM) has received 510(k) clearance by the FDA and can now be market launched.
SharePlan™ is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy® Hi•Art® systems and conventional linear accelerators. The product uses highly sophisticated algorithms to automatically generate a selection of deliverable high-quality IMRT plans based on an existing Hi•Art® plan. This time-saving concept is an important tool for optimizing patient benefit and throughput at clinics that are introducing a Hi-Art® system into an environment with existing conventional linear accelerators.
“We put great pride in our collaboration with TomoTherapy and have been working intensely on this product for little over a year so of course it feels very rewarding that we now reach the market. Hi•Art® users expect cutting-edge technological solutions and I am convinced that SharePlan will live up to their standards. Automatic plan generation is a revolutionary treatment planning concept that offers unparalleled user-friendliness and has the potential to dramatically reduce the everyday workload spent on routine tasks,” says Johan Löf, President of RaySearch.
“Our success is not just based upon delivering the highest quality radiation therapy,” according to Del Coufal, Vice President of Marketing for TomoTherapy. “We understand how important it is for TomoTherapy® technology to seamlessly integrate into a cancer center, regardless of the type of surrounding equipment the center also uses. By aligning with industry-leading strategic partners like RaySearch, we are able to make it easy for any center to easily adopt our revolutionary radiotherapy system.”
ABOUT TOMOTHERAPY TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi•Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi•Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO.
To learn more about TomoTherapy, please visit TomoTherapy.com.
ABOUT RaySearch RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are sold through license agreements with leading partners such as Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have been released to date and RaySearch’s software is used at over 1,300 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the SmallCap segment on the OMX Nordic Exchange Stockholm.
For more information about RaySearch, please visit www.RaySearchlabs.com.
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.